HERPESVIRUS INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS

被引:69
|
作者
STEWART, JA
REEF, SE
PELLETT, PE
COREY, L
WHITLEY, RJ
机构
[1] CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,ATLANTA,GA 30333
[2] UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195
[3] UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195
[4] UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195
[5] UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294
[6] UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35294
[7] UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294
关键词
D O I
10.1093/clinids/21.Supplement_1.S114
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Herpesviruses are among the most common causes of infections of humans. Viruses in this family share the unique biological property of being able to establish latency and to recur, Furthermore, chronic excretion of virus is not uncommon, In the immunocompromised host, including persons with human immunodeficiency virus (HIV) infection, herpesvirus disease can be particularly severe, resulting in chronic, persistent, active infection and, in some cases, life-threatening disease. The most pathogenic of the herpesviruses in patients with AIDS include herpes simplex viruses, human cytomegalovirus, and varicella-zoster virus, Disease caused by Epstein-Barr virus, particularly opportunistic malignancies, has been recognized, A new herpesvirus that is associated with Kaposi's sarcoma was recently described. On the other hand, disease caused by human herpesviruses 6 and 7 in persons infected with HIV remains to be unequivocally recognized. Prevention of exposure to herpesviruses, disease, and recurrence requires different measures than those for some of the other opportunistic infections in HIV-infected patients; this is because herpesvirus disease develops in most of these individuals as a result of reactivation rather than primary infection. Thus, approaches to the prevention and control of herpesvirus infections must be individualized according to both the type of virus as well as the type of infection (i.e., primary or recurrent). We discuss recommended measures for the prevention and control of these infections.
引用
收藏
页码:S114 / S120
页数:7
相关论文
共 50 条
  • [11] A PITIFULLY SMALL NUMBER OF PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    不详
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 1990, 90 (10): : 886 - 886
  • [12] PROSPECTS FOR PREVENTING CRYPTOCOCCOSIS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    PINNER, RW
    HAJJEH, RA
    POWDERLY, WG
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S103 - S107
  • [13] PREVENTING TOXOPLASMIC ENCEPHALITIS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    RICHARDS, FO
    KOVACS, JA
    LUFT, BJ
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S49 - S56
  • [14] TUBERCULOSIS AS AN OPPORTUNISTIC DISEASE IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    CASTRO, KG
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S66 - S71
  • [15] USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - INTRODUCTION
    KAPLAN, JE
    MASUR, H
    HOLMES, KK
    MCNEIL, MM
    SCHONBERGER, LB
    NAVIN, TR
    HANSON, DL
    GROSS, PA
    JAFFE, HW
    LANIER, D
    SCHRAM, N
    COOPER, E
    FREEDBERG, KA
    MAYER, K
    BLINKHORN, R
    ELLNER, J
    ANGULO, F
    BERKELMAN, R
    BREIMAN, R
    BRYAN, R
    BUEHLER, J
    CLADWELL, B
    CASTRO, K
    CHILDS, JE
    CHU, S
    CIESIELSKI, C
    DROTMAN, DP
    EDLIN, B
    ELLERBROCK, T
    FLEMING, P
    GEITER, L
    HAJJEH, R
    HANSON, D
    HOLMBERG, S
    HUGHES, J
    JAFFE, H
    JONES, J
    JURANEK, D
    KAPLAN, JE
    KELLER, D
    MARTONE, W
    MILLER, B
    NAVIN, T
    NESLUND, V
    OSTROFF, S
    PELLETT, PE
    PINNER, R
    REEF, S
    REEVES, WC
    REGNERY, R
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S1 - S11
  • [16] USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - AN OVERVIEW
    KAPLAN, JE
    MASUR, H
    HOLMES, KK
    WILFERT, CM
    SPERLING, R
    BAKER, SA
    TRAPNELL, CB
    FREEDBERG, KA
    COTTON, D
    POWDERLY, WG
    JAFFE, HW
    LANIER, D
    SCHRAM, N
    COOPER, E
    MAYER, K
    BLINKHORN, R
    ELLNER, J
    ANGULO, J
    BERKELMAN, R
    BREIMAN, R
    BRYAN, R
    BEUHLER, J
    CALDWELL, B
    CASTRO, K
    CHILDS, JE
    CHU, S
    CIESIELSKI, C
    DROTMAN, DP
    EDLIN, B
    ELLERBROCK, T
    FLEMING, P
    GEITER, L
    HAJJEH, R
    HANSON, D
    HOLMBERG, S
    HUGHES, J
    JAFFE, H
    JONES, J
    JURANEK, D
    KELLER, D
    MARTONE, W
    MCNEIL, MM
    MILLER, B
    NAVIN, T
    NESLUND, V
    OSTROFF, S
    PELLETT, PE
    PINNER, R
    REEF, S
    REEVES, WC
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S12 - S31
  • [17] PREVENTING BACTERIAL RESPIRATORY-TRACT INFECTIONS AMONG PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    KELLER, DW
    BREIMAN, RF
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S77 - S83
  • [18] INDICATORS FOR ASSESSMENT OF COMPLIANCE WITH QUALITY STANDARDS FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    GROSS, PA
    KAPLAN, JE
    PHAIR, JP
    MASUR, H
    WILFERT, CM
    HOLMES, KK
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S138 - S141
  • [19] IDENTIFICATION OF MYCOPLASMAS IN URINE FROM PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    CHIRGWIN, KD
    CUMMINGS, MC
    DEMEO, LR
    MURPHY, M
    MCCORMACK, WM
    CLINICAL INFECTIOUS DISEASES, 1993, 17 : S264 - S266
  • [20] HUMAN PAPILLOMAVIRUS INFECTION AND ASSOCIATED DISEASE IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    VERNON, SD
    HOLMES, KK
    REEVES, WC
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S121 - S124